Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1562
http://purl.obolibrary.org/obo/NCIT_C1562
|
|---|---|
| Preferred Name | Rhenium Re 186 Etidronate |
| Definitions |
An synthetic compound containing the organic phosphonate hydroxyethylidene diphosphonate (HEDP) labeled with the radioisotope rhenium Re 186. Re-186 etidronate binds to hydroxyapatite in bone, delivering a cytotoxic dose of beta radiation to primary and metastatic bone tumors. Re-186 is a beta emitter with a short half-life, a radioisotope profile that provides localized antitumor radiocytotoxicity while sparing extramedullary bone marrow tissues.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An synthetic compound containing the organic phosphonate hydroxyethylidene diphosphonate (HEDP) labeled with the radioisotope rhenium Re 186. Re-186 etidronate binds to hydroxyapatite in bone, delivering a cytotoxic dose of beta radiation to primary and metastatic bone tumors. Re-186 is a beta emitter with a short half-life, a radioisotope profile that provides localized antitumor radiocytotoxicity while sparing extramedullary bone marrow tissues. |
|---|---|
| prefLabel | Rhenium Re 186 Etidronate
|
| label | Rhenium Re 186 Etidronate
|
| PDQ_Closed_Trial_Search_ID | 41205
|
| code | C1562
|
| prefixIRI | NCIT:C1562
|
| in_subset | |
| Preferred_Name | Rhenium Re 186 Etidronate
|
| FDA_UNII_Code | DV7W6W681S
|
| Contributing_Source | FDA
|
| Maps_To | Rhenium Re-186 Hydroxyethylidene Diphosphonate
|
| CAS_Registry | 140709-07-5
|
| NCI_Drug_Dictionary_ID | 41205
|
| Legacy Concept Name | Re_186_Hydroxyethylidene_Diphosphonate
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 41205
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0280809
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |